Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion

• Status: Completed
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is prospective randomized control trial study. The aim of this study is to evaluate the efficacy of Iodopovidone solution for pleurodesis in palliative malignant pleural effusion (MPE) patients comparing to Talc. All adult patients who diagnosed MPE by cytology regardless primary tumor between December 1, 2015 and November 29, 2016 at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand will be enrolled in this study. The inform and consent will be applied in all patients before treatment. Patients will be randomized to two groups; Iodopovidone group (intervention group) and Talc group (control group)

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chiang Mai University
• Treatments: Pharmaceutical Solutions; Povidone; Povidone-Iodine

Criteria

Inclusion Criteria:

1. All MPE proved by cytology

2. After pleural effusion was released by chest tube drainage, lung was fully expanded

Exclusion Criteria:

1. Patients who have Karnofsky performance state ≤ 40

2. History of iodine allergy

3. History of morphine allergy

4. Abnormal thyroid hormones.